Back to Search Start Over

Endoscopic activity, tissue factor and Crohn's disease: findings in clinical remission patients.

Authors :
Andrade AR
da Rocha TRF
Ortiz-Agostinho CL
Nishitokukado I
Carlos AS
de Azevedo MFC
Hashimoto CL
Damião AOMC
Carrilho FJ
D'Amico E
Sipahi AM
de Arruda Leite AZ
Source :
Therapeutic advances in gastroenterology [Therap Adv Gastroenterol] 2020 Aug 03; Vol. 13, pp. 1756284820939412. Date of Electronic Publication: 2020 Aug 03 (Print Publication: 2020).
Publication Year :
2020

Abstract

Background: As Crohn's disease (CD) is associated with a high risk of thromboembolic events (TE), including patients with subclinical inflammation, we aim to evaluate the correlation between the impact of endoscopic activity (EA) in the coagulation profiling of CD patients while in clinical remission.<br />Methods: From 164 consecutive CD patients included in clinical remission [Crohn's disease activity index (CDAI) < 150], 75 were in the EA group [Simplified Endoscopic Score for CD (SES-CD) ⩾ 7], 89 were in the endoscopic remission (ER) group (SES-CD ⩽ 2), and 50 were included as healthy controls in the study. Blood samples were analyzed for tissue factor (TF), factor VIII (FVIII), thrombomodulin (TM), ADAMTS-13, von Willebrand factor (VWF), and endogenous thrombin potential (ETP), as well as collecting data regarding risk factors for TE and CD profile.<br />Results: Mean plasma TF activity showed significantly higher levels in the EA group when compared with the ER and control groups (127 pM versus 103 pM versus 84 pM; p  = 0.001), although the VWF:Ag (160% versus 168% versus 110%; p  = 0.001), VWF/ADAMTS-13 (191 versus 219 versus 138; p  = 0.003), FVIII (150% versus 144% versus 90%; p  = 0.001) and TM (5.13 ng/ml versus 4.91 ng/mL versus 3.81 ng/ml; p  < 0.001) were only increased in CD regardless of EA status when compared with controls. Lastly, ETP with and without TM remained the same in all three groups.<br />Conclusions: CD patients in clinical remission with EA present endothelial lesion inducing TF exposure and subsequent coagulation cascade activation. Recommended thromboprophylaxis for EA outpatient subgroups will require additional investigation in order to be validated.<br />Competing Interests: Conflict of interest statement: The authors declare that there is no conflict of interest.<br /> (© The Author(s), 2020.)

Details

Language :
English
ISSN :
1756-283X
Volume :
13
Database :
MEDLINE
Journal :
Therapeutic advances in gastroenterology
Publication Type :
Academic Journal
Accession number :
34025780
Full Text :
https://doi.org/10.1177/1756284820939412